

Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials

Usha Menon^{1*}, Aleksandra Gentry-Maharaj^{1,2},
Matthew Burnell¹, Sophia Apostolidou¹, Andy Ryan¹,
Jatinderpal K Kalsi³, Naveena Singh⁴, Lesley Fallowfield⁵,
Alistair J McGuire⁶, Stuart Campbell⁷, Steven J Skates⁸,
Anne Dawnay⁹, Mahesh Parmar¹ and Ian J Jacobs²
on behalf of the UKCTOCS team

¹MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK

²Department of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

³Institute of Epidemiology and Health Care, University College London, London, UK

⁴Department of Cellular Pathology, Barts Health NHS Trust, London, UK

⁵Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK

⁶London School of Economics and Political Science, London, UK

⁷Create Health, London, UK

⁸Massachusetts General Hospital and Harvard Medical School, Boston, USA

⁹Department of Clinical Biochemistry, Barts Health NHS Trust, London, UK

*Corresponding author

Disclosure of interests of authors

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at <https://doi.org/10.3310/CLDC7214>.

Primary conflicts of interest: Usha Menon had stock ownership awarded by University College London (UCL) until October 2021 in Abcodia, which holds the licence for ROCA. She has received grants from the Medical Research Council (MRC), Cancer Research UK, the National Institute for Health and Care Research (NIHR), and The Eve Appeal. She holds patent number EP10178345.4 for Breast Cancer Diagnostics. She received an honorarium for a lecture from NY Obstetrical Society (USA), and was reimbursed for travel by NY Obstetrical Society, National Cancer Policy Forum, USA and Robinson College, Cambridge. She has been a member of International Alliance for Cancer Early Detection (ACED); Tina's Wish Scientific Advisory Board (USA); Data Monitoring Committee: Mixed COVID Vaccines study, India; Research Advisory Panel, Yorkshire Cancer Research; GCP Professional Certification Scheme Steering committee, CDSA, India; Clinical and Public Health Fellowship Selection Committee, Wellcome Trust DBT India Alliance; Prevention Expert Review Panel, Population Research Committee, CRUK; Early Career Fellowship Selection Committee, Wellcome Trust DBT India Alliance; and Chair of Data Monitoring Committee for GEM3. Usha Menon reports funding from UCL Hospital Biomedical Research

Centre, paid to UCL. Usha Menon, Aleksandra Gentry-Maharaj, Andy Ryan, Matthew Burnell and Sophia Apostolidou report funding from CRUK, The Eve Appeal, NIHR HTA, MRC and NIHR, all paid to UCL. Usha Menon, Aleksandra Gentry-Maharaj and Sophia Apostolidou report research collaboration contracts with Cambridge University, QIMR Berghofer Medical Research Institute, iLOF (intelligent Lab on Fiber), RNA Guardian, Micronoma, Mercy Bioanalytics, Synteny Biotechnology, Imperial College, London and Dana Farber Cancer Institute Inc., University of Innsbruck and National Health and Medical Research Council (NHMRC), Australia. Alexandra Gentry-Maharaj is a member of ACED Gynaecological Cancer Working Group and is ACED Co-Director Research Domain Trials. Sophia Apostolidou reports funding to UCL from Abodia. Mahesh Parmar was an Associate Member of the EME funding committee while the project was active. Mahesh Parmar has received grants and Aleksandra Gentry-Maharaj, Matthew Burnell and Andy Ryan have been funded by grants from MRC, Cancer Research UK, NIHR, and The Eve Appeal. Steven J Skates co-developed ROCA in 1995. It was patented by Massachusetts General Hospital and Queen Mary University of London and is owned by these universities. The patent has expired. Massachusetts General Hospital and Queen Mary University of London granted a licence for the ROCA to Abcodia in 2014. He reports stock options from SISCAPA Assay Technologies. Steven J Skates reports grant support from National Cancer Institute (USA), NIHR (UK) and Mercy Bioanalytics. He participated in the Independent Data Monitoring Committee for GRAIL, served on the clinical advisory board for Guardant Health and Scientific Advisory Board for LUNGeivity, and holds stock options for service on Scientific Advisory Board of SISCAPA Assay Technologies. He also has a collaboration agreement with Freenome. Ian J Jacobs reports grants from Eve Appeal Charity, MRC, Cancer Research UK, and NIHR during the conduct of the study. He co-invented the ROCA in 1995; it was patented by Massachusetts General Hospital and Queen Mary University of London and is owned by these universities. Massachusetts General Hospital and Queen Mary University of London granted a licence for the ROCA to Abcodia in 2014. Ian J Jacobs is non-executive director, shareholder, and consultant to Abcodia and has rights to royalties from sales of the ROCA. He founded (1985), was a trustee of (2012–4), and is now an Emeritus trustee (2015–present) of The Eve Appeal, one of the funding agencies for UKCTOCS. Lesley Fallowfield reports MRC funding for the psychosocial arm of the UKCTOCS study 2001–13, paid to University of Sussex. Naveena Singh received honoraria from Astra-Zeneca-MSD and GlaxoSmithKline for participation in advisory boards. Alistair McGuire was a member of NIHR HTA and EME Editorial Board (2012 to 2022). Ranjit Manchanda reports funding from The Eve Appeal, Rosetrees Charity, Barts Charity, Yorkshire Cancer Research, Ovacure, British Gynaecological Cancer society (BGCS), Astrazeneca and GlaxoSmithKline (GSK). All other authors declare no competing interests.

Published August 2023
DOI: 10.3310/CLDC7214

This article should be referenced as follows:

Menon U, Gentry-Maharaj A, Burnell M, Apostolidou S, Ryan A, Kalsi JK, *et al.* Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials [published online ahead of print August 23 2023]. *Health Technol Assess* 2023. <https://doi.org/10.3310/CLDC7214>

Abstract

Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials

Usha Menon^{1*}, Aleksandra Gentry-Maharaj^{1,2}, Matthew Burnell¹,
Sophia Apostolidou¹, Andy Ryan¹, Jatinderpal K Kalsi³,
Naveena Singh⁴, Lesley Fallowfield⁵, Alistair J McGuire⁶,
Stuart Campbell⁷, Steven J Skates⁸, Anne Dawnay⁹, Mahesh Parmar¹
and Ian J Jacobs² on behalf of the UKCTOCS team

¹MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK

²Department of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

³Institute of Epidemiology and Health Care, University College London, London, UK

⁴Department of Cellular Pathology, Barts Health NHS Trust, London, UK

⁵Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK

⁶London School of Economics and Political Science, London, UK

⁷Create Health, London, UK

⁸Massachusetts General Hospital and Harvard Medical School, Boston, USA

⁹Department of Clinical Biochemistry, Barts Health NHS Trust, London, UK

*Corresponding author u.menon@ucl.ac.uk

Randomised controlled trials are challenging to deliver. There is a constant need to review and refine recruitment and implementation strategies if they are to be completed on time and within budget. We present the strategies adopted in the United Kingdom Collaborative Trial of Ovarian Cancer Screening, one of the largest individually randomised controlled trials in the world. The trial recruited over 202,000 women (2001–5) and delivered over 670,000 annual screens (2001–11) and over 3 million women-years of follow-up (2001–20). Key to the successful completion were the involvement of senior investigators in the day-to-day running of the trial, proactive trial management and willingness to innovate and use technology. Our underlying ethos was that trial participants should always be at the centre of all our processes. We ensured that they were able to contact either the site or the coordinating centre teams for clarifications about their results, for follow-up and for rescheduling of appointments. To facilitate this, we shared personal identifiers (with consent) with both teams and had dedicated reception staff at both site and coordinating centre. Key aspects were a comprehensive online trial management system which included an electronic data capture system (resulting in an almost paperless trial), biobanking, monitoring and project management modules. The automation of algorithms (to ascertain eligibility and classify results and ensuing actions) and processes (scheduling of appointments, printing of letters, etc.) ensured the protocol was closely followed and timelines were met. Significant engagement with participants ensured retention and low rates of complaints. Our solutions to the design, conduct and analyses issues we faced are highly relevant, given the renewed focus on trials for early detection of cancer.

Future work: There is a pressing need to increase the evidence base to support decision making about all aspects of trial methodology.

Trial registration: ISRCTN-22488978; ClinicalTrials.gov-NCT00058032.

Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/46/01.

The long-term follow-up UKCTOCS (2015–20) was supported by National Institute for Health and Care Research (NIHR HTA grant 16/46/01), Cancer Research UK, and The Eve Appeal. UKCTOCS (2001–14) was funded by the MRC (G9901012 and G0801228), Cancer Research UK (C1479/A2884), and the UK Department of Health, with additional support from The Eve Appeal. Researchers at UCL were supported by the NIHR UCL Hospitals Biomedical Research Centre and by the MRC Clinical Trials Unit at UCL core funding (MC_UU_00004/09, MC_UU_00004/08, MC_UU_00004/07). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health and Social Care.

List of abbreviations

CA125	cancer antigen 125	PIS	patient information sheet
CC	coordinating centre	PPI	patient and public involvement
CRF	case report form	QC	quality control
DSA	data-sharing agreement	RC	regional centre
ECE	eligibility criteria effect	RCHD	routinely collected health-care data
eDC	electronic data capture	RCT	randomised controlled trial
GDPR	General Data Protection Regulation	ROCA	Risk of Ovarian Cancer Algorithm
GP	general practitioner	SWAT	study within a trial
HES	hospital episode statistics	TEA	The Eve Appeal
HR	hazard ratio	TMS	trial management system
HVE	healthy volunteer effect	UCL	University College London
ICD-10	<i>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision</i>	UCLH	University College London Hospital
MMS	multimodal screening	UKCTOCS	United Kingdom Collaborative Trial of Ovarian Cancer Screening
NIHR	National Institute for Health and Care Research	UKLWC	UKCTOCS Longitudinal Women's Cohort
ONS	Office for National Statistics	USS	ultrasound screening
PI	principal investigator		
PCT	primary care trust		

Plain language summary

Randomised controlled trials help us decide whether new health-care approaches are better than those in current use. To successfully complete these on time and within budget, there is a constant need to review and revise the procedures used for delivering various aspects such as invitation, enrolment, follow-up of participants, delivery of the new test, data collection, and analysis. We report on the processes used in the United Kingdom Collaborative Trial of Ovarian Cancer Screening, one of the largest such trials. The United Kingdom Collaborative Trial of Ovarian Cancer Screening enrolled over 202,000 women (2001–5), delivered over 670,000 yearly screens (2001–11) and followed all participants until 2020. Key to our successful completion were the involvement of senior investigators in day-to-day running of the trial, a pre-emptive approach to issues, a willingness to innovate, and the use of technology. Our underlying ethos was that trial participants should always be at the centre of all our processes. We ensured that they were able to always contact either their local or the central team for clarifications and rescheduling of appointments. To facilitate this, we shared participant contact details (with consent) with both teams. We built a comprehensive electronic system to manage all aspects of the trial. This included online forms that the teams completed in real time (resulting in an almost paperless trial) and systems to check and manage trial processes and track blood samples. We automated key steps such as checking whether participants were eligible, assigning correct action based on results of screening tests, scheduling appointments and printing letters. As a result, all participants were treated as set out in the trial plan. Our engagement with participants ensured that they continued participating and we had a low rate of complaints. We faced issues with regard to our initial trial design and the way we planned to analyse the data. We feel that our solutions are highly relevant, especially as there is a renewed focus on trials for early detection of cancer.

Introduction

Randomised controlled trials (RCTs) continue to be the cornerstone of evidence-based medicine. Between 2010 and 2021 there were over 12,000 trials, including over 9000 RCTs, registered with the ISCRTN registry of clinical trials.¹ Of the RCTs, 11% had target sample sizes of 1000 or more individuals, with 24 RCTs involving over 100,000 participants.

Design, conduct and analysis of such trials are always challenging. Despite the significant efforts to systematically advance trial methodology,² many RCTs still struggle to meet recruitment targets,³ retain participants, and report on time. A review of individually randomised single- or multi-centre RCTs funded by the UK Health Technology Assessment Programme between 2004 and 2016 found that only 40% of 151 RCTs achieved the original recruitment target sample size and 79% of them included 80% or more of the final target sample size.³ Delays and poor recruitment impact not only on duration but also on resource use and statistical power, with the worst-case scenario being discontinuation of the trial.⁴ The focus on scientific outcomes often means that the lessons learnt and solutions individual trials adopt to overcome some of these hurdles are not routinely shared within the trials community.

The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), with 202,638 participants, is among the largest RCTs with individual randomisation. While the original target size of 200,000 was exceeded, the trial's conduct was not without challenges. It required inviting over 1.2 million women and using novel and innovative approaches to achieve timely recruitment. About 7 years after the trial started, having overcome the hurdles of recruitment and retention, UKCTOCS still faced a challenge that it would not report on time. The impact of eligibility criteria and a healthy volunteer effect (HVE) contributed to the slow accrual of events (ovarian cancer deaths) in the control (no screening) arm.⁵ To maintain power, the end date of the trial was extended to accommodate longer follow-up, and as a result annual screening took place for 7–11 years rather than the original 6 years. Finally, when the primary outcome was reported, the lack of definitive results meant that there was a need for extended follow-up.⁶ In addition to scale, the other challenge specific to population screening trials is the need to ensure that screening and any ensuing investigations and treatment are delivered safely and at pre-stipulated regular intervals. In UKCTOCS, this involved delivering over 670,000 annual screens to the over 100,000 women randomised to the intervention arms and performing over 2500 operations for those found to have an abnormality (screen positive). This was enabled by a long-term commitment and exemplary collaborative partnership involving participants, trial teams, health-care professionals, hosting NHS Trusts and universities, patient charities and funding agencies. This partnership was described as a major achievement for clinical science in the NHS, with the philosophy that underpinned UKCTOCS hailed as a crucial part of an integrated health service that should be applauded and fostered. The Lancet. UKCTOCS and the evaluation of screening for ovarian cancer. Lancet. 2016 Mar 5;387(10022):918. doi: 10.1016/S0140-6736(16)00631-0. Epub 2016 Mar 4. PMID: 26972235.

Here, we summarise the challenges we faced and the solutions that helped us achieve this success, and detail some of the outstanding issues that need to be addressed. Despite UKCTOCS being designed in the late 1990s, with recruitment in the early 2000s, the innovative approaches we adopted and the lessons learnt in the course of almost two decades of follow-up are still pertinent. Many apply to all trials, while some are specific to population screening trials.

Design and analysis

The issues discussed below, though more applicable to screening trials, are relevant to treatment trials too.

Estimation of accrual of events (primary outcome)

A key factor in the power calculation that underpins any trial design is the number of primary outcome events in the control arm. An important consideration in the design of any trial with time-to-event data is the prediction of when these events will occur, and specifically how long it will take to accumulate the necessary number of control arm events implicit in calculations used to power the study. This involves the specification of a target sample size to be randomised plus a follow-up period. Accordingly, it is important that event rate prediction is as accurate as feasible, incorporating relevant and knowable factors.

In the initial design of UKCTOCS, the sample size calculations required a control event (ovarian cancer death) count of 222. To achieve this figure in terms of trial design, a simple calculation was employed: a prediction of 37 ovarian cancer deaths per 100,000 women per year based on national ovarian cancer mortality statistics in women aged ≥ 50 years. Six years of annual screening plus 1 year of additional follow-up, with an annual 4% 'attrition rate', was deemed adequate total analysis time to accumulate the required 222 events.⁶

At a median follow-up of 5 years from randomisation, it was apparent that there were significantly fewer events in the control arm than originally estimated.⁵ Our assumption, widely used, that mortality would be similar to the Office for National Statistics (ONS) data was one source of potential error. We, like many others, did not consider the impact of the eligibility criteria effect (ECE), which relates to the fact that all cancer screening and prevention trials will exclude those previously diagnosed with the cancer under study as well as those actively undergoing treatment for other cancers. In screening trials, this results in cancer-specific deaths occurring only in those diagnosed after randomisation. In UKCTOCS, in the control group, we estimated 37 ovarian cancer deaths per year. However, the total number of deaths in the first 2 years was only 18, as events were limited to deaths within 2 years of clinical diagnosis of ovarian cancer. When we revised our event rate calculation, we made an adjustment for the ECE, using external data on age- and period-relevant survival rates from time of clinical diagnosis.

Event rate calculations in the control arm were again needed for planning extended follow-up at the end of 2014 as our mortality analysis did not provide definitive results. We targeted an additional 233 control group ovarian cancer deaths, but on this occasion did not use predictions based on external data.⁷ Rather, we used ovarian cancer mortality data from within our trial over the initial 13.6-year period for extrapolation using flexible parametric survival models, with adjustment for all-cause mortality. Although the models themselves can fit data to an arbitrarily close degree, as events are predicted beyond the range of the data, the extrapolation is close to a simple linear extension. It is not guaranteed that this method will prove more accurate than those based on external data as one cannot be sure that past trends will continue into the future. As it turned out, during regular event rate monitoring during extended follow-up, our initial calculations extrapolating past data proved a moderate overestimate, and the date of trial end was delayed by over a year from 31 December 2018 to 30 June 2020.

In addition to the above, there was an healthy volunteer effect (HVE). Those who tend to volunteer for health intervention studies are likely to be more health orientated and consequently less likely to succumb to the disease of interest compared to the national average rate.^{8,9} As a result, the incidence

and mortality rates of many cancers and major diseases were considerably less than those reported in the national statistics.⁵

To maintain power and have the requisite number of events, like most, we decided it was more productive (and logistically simpler) to increase the follow-up time of randomised trial participants rather than recruit additional volunteers. Instead of each participant having an individual end date and a total of 7 years' follow-up from randomisation, we extended follow-up with a common end date (31 December 2014) for all participants. As recruitment occurred between 2001 and 2005, this resulted in each volunteer having a different total follow-up time, giving the added complication of individual event rate predictions. To future-proof the revised calculation, we included not just individual age-adjusted risks but also the risk increase associated with ageing and the predicted losses to follow-up from other-cause mortality (i.e. excluding ovarian cancer). We therefore extended annual screening to the end of 2011 to ensure that there was minimal dilution of the screening effect. This resulted in screen arm participants having a maximum of 7–11 annual screens, depending on when they were recruited (2001–5), instead of the originally planned six annual screens.

Our experience highlights a common error of assuming national event rates when calculating target sample size in a clinical trial. Such an approach often leads to a significant shortfall of primary outcome events. This is likely magnified in early detection or prevention trials, where the eligibility criteria and the nature of the intervention being evaluated skew participation in favour of those who adopt healthy lifestyle behaviours such as exercise and balanced diet. The cause-specific standardised mortality/incident ratios of cancers and other diseases in our publication⁵ provide useful guidance when estimating the likely refactoring of national statistics-based calculations that is required in order to provide a more realistic event rate that accounts for a HVE.

An interesting final note was that at the end of the trial (median follow-up 16.3 years), it was apparent from the trend of the standardised mortality ratios for ovarian cancer over time that there was no HVE with regard to ovarian cancer. Ovarian cancer incidence in the control arm was similar to, if not higher than, national figures available at the start of the trial, and the mortality was as expected after years 6–8 post randomisation. It may be surmised that the initial shortfall, discounting the simplistic early calculations, was solely due to the ECE. This may not be surprising in the particular case of ovarian cancer, because UKCTOCS participants were found to be less socially deprived (lower Index of Multiple Deprivation scores) compared with those invited.⁵ It is well established that ovarian cancer, unlike most others, is associated with more affluent populations.^{7,10} By contrast, a general population screening trial in lung cancer, for example, should certainly factor for a likely HVE in event rate calculation.

It is important to note that even with the best possible assumptions, the predictions may differ greatly from the eventual outcome, and regular monitoring of control events and recalibrations of those predictions is highly advisable.

Primary analysis approach

The method of the primary analysis chosen for a cancer screening trial is a crucial part of the trial planning process. It is important to note firstly that over the last two decades the mortality results from cancer screening trials have repeatedly shown that when there is a positive screening effect, it appears after a period of delay,^{11–15} even up to 7 years post trial randomisation.¹⁶ This is consistent with how screening aims to prevent deaths by detecting cancers early, before they reach an incurable state. The delay reflects the time required for participants in the control group to develop symptomatic disease and subsequently die of it, in substantial numbers. Additionally, in the early years post randomisation, opportunity to detect these cancers sufficiently early in their natural history is limited and, as a result, screening has less impact in preventing cancer deaths.^{17,18}

There are several aspects one may wish to consider when developing the (primary) analysis plan, and those elements will not all necessarily be in concordance. An obvious goal is to maximise statistical power. This can be done by adopting a statistical test that accommodates the late effects typical of cancer screening, either through giving higher weighting to later events or by specifically modelling the non-proportional hazard functions of the screen and control arms. However, screening trials have historically used simple methods, usually a single Poisson-based rate ratio^{11,14,16,19-21} or a Cox model with a single hazard ratio (HR)^{12,13} to estimate the mortality benefit. These methods will give a clear, easy to interpret result – a key analytical consideration, which is presumably why they are popular. However, the estimated screening effect indicated by a HR could be a gross simplification of the true nature of the screening trial. Reduction to a single summary estimate will provide a misleading impression of the impact of the screening regimen being evaluated, both on the thousands of participants screened in the trial and on what may be expected in the future.

Our experiences from UKCTOCS show the difficulties in reconciling the opposing forces of simplicity and ease of interpretability versus reflecting reality and a more relevant interpretation, with the added complication of statistical power. Our trial, like many others, initially used a proportional hazards Cox model for our primary analysis, and the first reporting of mortality data gave a non-significant result that suggested a late separation of the mortality curves at possibly 7 years post randomisation.²² With further follow-up, and all subsequent events occurring in that post-separation period, it was hoped that the extended follow-up analysis might provide an unambiguous positive result. A lengthy period of introspection and debate within the trial management group and trial steering committee regarding the appropriate choice of primary analysis for long-term follow-up ensued. We ultimately dealt with this dilemma by formally seeking the counsel of 12 statistical and screening experts, the majority of whom gave backing to methods that reflected the non-proportionality expected in successful screening trials.²³ More generally, they also supported the concept of the pragmatic evidential approach, which challenges the fixed pre-specification viewpoint that would have prevented this alteration to the primary analysis.

That the long-term results for UKCTOCS unfortunately showed no discernible screening benefit should not affect the relevance and importance of these considerations. That said, there is naturally a reputational risk inherent in changing the statistical analysis plan after a portion of the data has been unblinded. Hence we would strongly advise that in the planning phase of a cancer screening trial, the extent of the projected screening effect delay be carefully deliberated. One should use current understanding of the natural history of the cancer of interest and other relevant factors to try and predict, as much as feasible, the likely time interval to mortality curve separation, as this will influence the most appropriate modelling choice. This applies in terms of both interpretation and power. The longer the delay in screening benefit, the greater statistical benefit to abandoning the proportional hazards approach. However, when the delay is modest, such as 3 years or less, it should also be cautioned that a late-weighted model will not necessarily give greater power, especially when total events will be low in the early years. In fact, if the final data suggest a result not dissimilar to proportional hazards, then the penalty paid in terms of power may even be greater than that for choosing proportional hazards in a scenario with more obvious late effects.^{24,25} For that reason, one may consider a method for the primary analysis such as the Versatile test²⁶ which will provide high, if not optimal, statistical power in all potential scenarios, obviating the need for accurate prediction of relative hazard functions. More complicated modelling techniques may also be utilised for estimation purposes.

Appropriate secondary analyses of primary outcome

As has been described already, it is crucial that the primary analysis is carefully considered and should reflect prior beliefs about the anticipated screening effect. It is also important that a similar level of prior thought is given to the secondary analyses of the primary outcome detailed in the statistical analysis plan. There is a tendency to list a number of additional analyses of the primary outcome, in an attempt to cover many bases. It is also tempting to deviate from the secondary analyses of the primary

outcome detailed in the statistical analysis plan as new information and ideas come to light. Given we changed the primary analysis after extended follow-up, we do not suggest that aspects of secondary analyses should not be changed. However, it needs to be noted that excessive secondary analyses have the potential both to distract from the primary analysis and to impact on the message produced at the time of the final mortality analysis. Our first mortality analyses²² probably suffered from describing too many results, which proved hard for many readers to absorb. The prior-defined primary analysis was perhaps also compromised by the inclusion of a complicated secondary analysis as well as a post hoc analysis. We would therefore strongly urge that it is important to reconsider the inclusion of secondary analyses of the primary outcome that differ only slightly from the primary. Certainly, additional analyses that require significant description of methodology are probably best not included in the publication reporting the primary outcome of the trial. Indeed, important other analyses are best considered for a separate publication instead, to give them the breadth the data deserve.

Conduct

Our vision, which guided all aspects of implementation, was that trial participants needed to be at the centre of all we did. They were investing their trust, time and health to support our endeavour. To this end, all trial processes were adapted to ensure safety, timely correspondence, and minimise any inconvenience participants might encounter.

Set-up

The trial was set up to be delivered through 13 sites [regional centres (RCs)]. The number was chosen to ensure that there was a balance between the distance women would have to travel to participate in the trial, the number of centres which the trial coordinating centre (CC) could support and monitor to a high standard and the efficient use of the pelvic ultrasound scanning machine which was purchased for each RC. Similar set-up has been described where the same prototype device has been used in triage of patients with cervical abnormalities on colposcopy or cytology in a smaller multicentre trial.²⁷ Each UKCTOCS RC had a dedicated trial team and ring-fenced trial space. Significant efforts were made to ensure that CC oversight of site teams released the site clinical principal investigators (PIs) from much of the workload associated with day-to-day running of the trial. The latter has since been found to be a key driver of successful trial recruitment in the Strategies for Trial Enrollment and Participation study.²⁸

Direct interaction between trial coordinating team and participants

To remain true to our guiding vision throughout our two-decade-long trial, we decided that participants should always be able to contact trial staff easily. We therefore decided to provide them with two options: they could contact the team at either their local RC or the CC with any queries. The patient information sheet (PIS) set this out clearly and enabled sharing of all data, including personal identifiers, with both teams. As a result, despite limited availability of RC PIs due to significant clinical workloads, turnover of RC staff, and eventually the closure of RCs at the end of screening in 2011, participants were always able to contact a core team at the CC who had access to all their information and could provide answers to any trial-related queries.

Trial management system

One of the core requirements of our decision to provide two sources of support to participants was that both RC and CC teams would need access to all trial information related to participants in real time. To this end we built a bespoke online trial management system (TMS) with many of the functionalities found nowadays in hospital management systems. All participant-facing trial activities were recorded directly on the system, and we limited use of paper case report forms (CRFs). Key elements were electronic data capture (eDC) of both CRF data and any discussions/conversations with participants, screening results look-up pages, set-up of all trial recruitment and screening clinics on the TMS, incorporation of an appointment scheduling system, and automated algorithms to ensure all actions were protocol-driven. The web browser and high-security encryption ensured data security, as did hosting the system within a data safe haven certified to the international information security standard ISO27001:2013²⁹ and conforming to NHS Digital's Data Security and Protection Toolkit.³⁰

The TMS automated importing of lists of names, addresses and general practitioner (GP) details of potential recruits (details below) from the primary care trusts (PCTs). Printing of invitations, trial recruitment and screening appointments and results letters was automated. Automated algorithms also determined eligibility based on recruitment questionnaire data, and randomised those eligible. Letters to participants and their GPs confirming randomisation group were printed automatically daily, alongside requests for missing eligibility information and letters stating reasons for ineligibility to those who could not be randomised. If ineligibility was related to age being < 50 years or interval from menopause

< 12 months, then the system would automatically contact these women when they became eligible with the passage of time. As participants attended the various clinics, they were checked in so that real-time recruitment data were available, as was attendance for ultrasound and blood screens. Scanning of the barcode blood requests at venepuncture clinics ensured that the CC could track all blood samples. The latter were transported daily to the central laboratory, where they were processed for the duration of the trial. In women randomised to the blood multimodal screening (MMS) group, the biomarker cancer antigen 125 (CA125) test result was directly uploaded from the central laboratory analyser into the TMS. For those randomised to the ultrasound screening (USS) group, the ultrasound examination findings were entered by the RC through the web pages. Automated classification algorithms ensured that results were accurately classified and appropriate actions such as return to annual screening or further appointment letters generated.

Overall, the TMS and the use of barcoding minimised where possible the necessity for manual data entry, thus reducing data transcription errors. Automating eligibility checking, randomisation, appointment scheduling and result classifications minimised protocol deviations throughout the course of the trial. Two decades after we built our TMS, web-based TMSs are increasingly becoming the norm for multicentre clinical trials. They include commercial eDC systems with simultaneous data entry from multiple sites using standard web browsers and centralised data processing, systems for site monitoring, electronic trial management files and biobanking modules incorporating laboratory information management systems that allow effective management of samples and associated data. Mobile eDCs³¹ are now increasingly used, with Research Electronic Data Capture (REDCap)³¹ being a popular non-profit alternative. None that we are aware of include automated study clinic appointment scheduling, and only bespoke solutions include test result processing. However, given the advances in accessible information technology, it is feasible for individual studies to tailor the available systems to meet their unique requirements.³²

In UKCTOCS, as in large multicentre screening trials, the additional use of automated classification algorithms ensured strict adherence to the protocol over a long period of time. Such solutions can be prohibitively expensive and are not available as off-the-shelf solutions. The UKCTOCS system cost almost £1M to build and maintain over the 20 years of the trial. There is now a more concerted move by research funding organisations to combine efforts and produce and support open-source solutions. This would empower a wider variety of investigators, including in resource-poor settings, to undertake research studies and achieve high-quality safety and data standards.

Recruitment

As in all trials, at the start, the key challenge was timely recruitment.³³⁻³⁵ This is magnified in general population screening and prevention trials which require large numbers of participants. UKCTOCS exceeded its target recruitment of 200,000 participants. During the recruitment phase (April 2001 to September 2005), the weekly average recruitment rate per centre was 96% (range 87–114%) of the weekly target of 100 women. Of note, this was accomplished with only 0.008% (98) of invited women complaining about recruitment-related problems: invitation to trial (32), trial information (28), recruitment appointment (17) and randomisation to control group (21).³⁶

The key factors responsible for our success are detailed below.

1. **Use of age–sex PCT registers to invite women from the general population** – The use of the electronic health records to identify women aged 50–74 years living in the vicinity of the 13 trial centres was crucial to ensuring that each centre met its monthly recruitment targets and that the allocated resources were maximally utilised. We obtained approval from 25 of the 27 individual PCTs to access contact details of women aged 50–74 years and their GPs. Specialised software that we commissioned from the NHS flagged the women whose details were shared on the PCT registers so

that they were not invited again. Over the course of the trial, we invited over 1.2 million (one in six eligible UK women aged 50–74 years), of whom only 32 complained about being contacted without specific consent.

In 2000, when the trial was planned, such processes were novel and bespoke. To address the significant recruitment challenges faced by researchers, this process has since been significantly streamlined through the set-up of patient registers such as the Scottish Health Research Register of those who have agreed for their clinical records to be used for research. Similarly, NHS Digital in England via its DigiTrials initiative is facilitating identification of potential trial participants. This includes the recent NHS Galleri Trial that has recruited 140,000 individuals to evaluate a new blood test for early detection of cancer.³⁷ In keeping with the current legal and research governance framework which prevents researchers from making direct contact with patients, invitations and information are sent via the clinician responsible for the care of the patient. Automated downloads from the NHS DigiTrials platform in the future for approved projects should further streamline this process. Routinely collected health-care data (RCHD) are also being accessed to determine the feasibility of RCTs.³⁸ An alternative is to use media advertisement alone, but this is more challenging. Two projects which have successfully recruited participants using the latter mode are UK Biobank³⁹ and the Scottish Diabetes Research Network.⁴⁰

The PCT lists enabled automated mass mailing of invitations from the CC using the TMS. An average of 2159 invitation letters were sent out every week during the recruitment phase. Key advantages of this approach included:

- i. Personalised invitations – Most women were sent an invitation letter addressed to them personally. This was not possible for those resident in two PCTs which did not agree to share contact details and sent out standard letters instead. While there was no significant difference in acceptance rates between these two PCTs and the 25 which enabled sharing of data in UKCTOCS,³⁶ on a somewhat related issue, a recent Cochrane Review of 24 studies on the uptake of cervical screening found that personalised invitations (targeted letters) rather than mass mailing appeared to be more effective.⁴¹ On acceptance, we sent the women a fixed appointment to attend for recruitment. The latter review also found that women sent fixed appointments were more likely to take up the offer of screening.⁴¹
- ii. Efficient flagging of recruited women for follow-up using NHS registers – inclusion of the NHS numbers in the shared contact details meant that we did not have to request these from either the women or their GPs. As a result, the data were complete and accurate, and we were able to efficiently link to electronic health records (cancer and death registers and routine hospital administrative data) for follow-up. Only 6 out of the 202,546 randomised eligible women could not be linked.²²
- iii. Informing GPs of all women invited for the trial – On receiving PCT lists of potential participants, automated processes in the TMS built a trial GP contact table and sent out a personal letter and an information pack to all GPs, who were only contacted once. Perhaps in the future, this could be done by e-mail in keeping with the need for ‘greener’ trials. Women were then sent invitations a minimum of a week later after their GP had been apprised of the trial. This ensured that no GP was unaware of the trial if their patient mentioned that she had been invited.
- iv. Ensuring recruitment resources were efficiently used – We arranged for 3-monthly electronic transfer of lists of 5000–10,000 women to the CC. The women were then invited to the trial. This approach minimised the number of invitations being sent to women who had died or moved away. Regular monitoring of acceptance rates helped establish the frequency and volume of mailing needed to ensure recruitment clinic appointments were full for the following 3 months. It also meant that women who accepted an invitation did not have to wait over 3 months for an appointment. Such a streamlined, partially automated approach safeguarded against delays and gaps in recruitment which would have had significant cost implications.

2. **Providing high-quality standardised patient information throughout recruitment** – This is a key requirement for all trials and is usually delivered through use of a standard PIS that has been approved by the overseeing ethics committee. We were aware that many patients did not read this detailed document. For us, additional challenges were the large number of participants, a recruitment period spanning 4.5 years, the multicentre set-up, individual research nurses recruiting an average of 100 women a week, and potential staff turnover. To address this, we developed further processes that included (1) an **information video**⁴²⁻⁴⁴ using a professional team and participants from our pilot screening trial. Such transmedia tools⁴⁵ helped ensure a low-cost, high-quality, easily implementable solution.³⁶ The women watched the video at the recruitment appointment in groups of six to eight. (2) A **group discussion** led by the trial nurse that would facilitate the more reticent to ask questions and hear others broach issues that viewing the video might have raised. (3) A **one-to-one discussion** with the research nurse that provided an opportunity to discuss any private/personal concerns. The use of an information video and group discussion during recruitment was a novel feature in 2000. The Sussex Health Outcomes Research and Education in Cancer team who helped develop the UKTOCS video has a long track record in producing excellent patient information videos. Some of the examples can be found here: <https://shore-c.sussex.ac.uk/trial-dvds.html>. Such an approach is being increasingly streamlined nowadays by incorporating podcasts that potential recruits can view prior to their recruitment appointment on trial websites or YouTube.⁴⁶ It is important to work with a professional team and involve trial participants and the lay public in producing such videos.

3. **Proactive management of recruitment** – The start of recruitment was phased across the 13 RCs. It was only started once adequate numbers of women had accepted the invitation, to ensure that recruitment appointments for 3 months were full at RC recruitment start. There was close monitoring of attendance at each of the recruitment clinics. Soon patterns emerged that were seasonal and sometimes RC-specific. For example, there was poor attendance during the summer holidays and during winter afternoons as it became dark earlier. To address this, we altered the clinic timings and overbooked scheduled appointment slots to ensure that the target of 100 per week was met as far as possible. When centres fell behind, additional large ad hoc ‘blitz’ clinics were set up, often on the weekend. These were a collaborative team effort, with CC staff travelling to the RC to assist local teams and senior staff including PIs joining in. They were supported using contingency funding, ring-fenced for such efforts.

The functionality we built into the TMS and the provision for participants to contact either the RC or CC administrative staff to reschedule the appointments led to more efficient use of resources. Overall, the TMS scheduled 1,109,351 trial appointments, of which 114,548 (10%) were rescheduled, in the main at the request of the participant. Overall, 8% (9149/114,548) of these rescheduled appointments were not attended, compared to 19% (186,098/994,803) of appointments that were not rescheduled.

Throughout the trial, there were monthly league tables of RC recruitment and vouchers for the winning team. There was a strong sense of camaraderie between all teams and a determination to make all aspects of the trial a success.

4. **Engaging with patient advocacy charities and media** – The uptake of invitations is impacted by individuals’ awareness of the trial and understanding of the relevance of the intervention being evaluated. From the start, we built a trial website which was regularly updated. To ensure that ovarian cancer screening and the trial were in the public domain, we worked closely with cancer (and particularly ovarian cancer) patient advocacy groups/charities and engaged with national and local media (TV, radio and newspapers). Trial investigators spoke regularly at the charity meetings and wrote articles for charity newsletters to raise awareness of the need for screening and to provide updates on trial recruitment and overall progress. We noted surges in uptake of invitations in response to some of the national media efforts. However, we did not collect data to measure impact. In the future, it would be worthwhile to consider a study within a trial (SWAT)⁴⁷ to prospectively assess the impact of such interactions on recruitment rates. Some of the published SWATs to date

exploring other recruitment strategies,⁴⁸ such as use of optimised information sheets,⁴⁹ advertising patient and public involvement (PPI)⁵⁰ to potential trial participants, pre-notification of trial detail,⁵¹ use of Post-It® Notes (3M, Saint Paul, MN, USA) in older patients,⁵² and impact of envelope colour⁵³ did not find significant impact on recruitment rates.

In addition to television and radio, since 2005 (end of UKCTOCS recruitment), a number of other digital tools – e-mail, social media⁵⁴ platforms such as Facebook (2006), Instagram, Twitter, data mining, and internet sites – have become increasingly available to create awareness and increase recruitment.⁴⁴ Most individuals, including older women such as those invited to UKCTOCS, have a mobile phone and an e-mail address. Social media engagement is much more prominent as a result of technological development and increasing acceptance. While no single platform will suit every study or every patient, the use of a combination of traditional (PIS, study brochures, radio and television advertisements) and social media tools is likely to increase successful recruitment.⁵⁴

There was one area where we did not do well. The trial did not have any ring-fenced resources for efforts to engage with minority or 'hard-to-reach' populations. All the invitations were in English. Given the age group we were targeting (50–74 years), the cohort is likely to have included women from minority populations who were unable to understand English. We did set up a facility for relatives of potential participants to ring and request a translator who would then explain the invitation content. However, this was seldom used, most likely as it required someone in the household to read the invitation we sent in English and contact us on behalf of the potential participant. There was not much use of the translating service for recruitment appointments either. We had hoped to set up a series of discussions on local minority-language radio stations but were unable to prioritise this. Overall, 96% of our participants were white, with rates varying from 97.9% to 99.4% in 10 of our 13 RCs. It was only in the two London RCs that we had significant minority participation, with over one in five from non-white communities (see [Appendix, Table 1](#)). When it came to the disabled community, too, our efforts were limited. We had a ticker tape (but not sign language) included in our video, which helped those with hearing impairment to some extent. We provided special appointments where individuals could request to view the video at their own pace with printed transcripts. Increasing minority participation has become a key aspect of trials over time. There are now recruitment strategies tailor-made to the participants' background.⁵⁴

Delivery of screening

We evaluated two screening tests: one involving a blood test for CA125 and the other using imaging (transvaginal ultrasound).

The blood test was operationally easier to deliver. We set up dedicated venepuncture clinics, which we were able to staff relatively easily. The biomarker CA125 is very stable and we were therefore able to set up daily transfers of the blood tubes at room temperature from the RC to the central laboratory where all the samples were processed. CA125 is a well-established cancer biomarker, routinely assayed in the NHS laboratories using automated platforms. Centralisation of CA125 analysis was required to ensure close monitoring of assay imprecision for the duration of the trial. In routine clinical use, imprecision is only monitored near the upper limit of the reference range (35 kU/l) and at an elevated level of about 120 kU/l. However, in UKCTOCS, CA125 was not interpreted using clinical cut-offs but a longitudinal algorithm [Risk of Ovarian Cancer Algorithm (ROCA)] which incorporates serial changes in CA125 and therefore required precision across the whole range of CA125 levels.⁵⁵ Most importantly, in the majority of the participants (older postmenopausal women), the normal CA125 levels were < 10 kU/l. Small changes in these levels could impact on the ROCA risk estimation. As there is no commercially available quality control (QC) sample available at such levels, we developed additional QC verified samples with concentrations in the range of 8–12 kU/l. We used serum samples and QCs to assess the effect of changes in the manufacturer's calibrator and reagent lots ahead of implementation and reserved at least

1 year's supply of the same lot number to minimise the frequency of change, a practice not available to routine clinical laboratories. Changes in calibrator, reagent and QC lot numbers were staggered to be at least 1 month apart, and the impact on ROCA intermediate and elevated risk rates was monitored daily for unexpected increases or decreases. After one reagent lot change was associated with an increase in these rates, we determined this was due to a positive constant error in the assay and thereafter included serum samples with very low (< 2 kU/l) CA125 values in our performance monitoring. With increasing focus on longitudinal biomarker algorithms for early detection, it is critical that trialists pay close attention to the inter- and intra-assay variability of the novel biomarkers being evaluated.

The transvaginal ultrasound was logistically much more challenging to deliver. Like other imaging modalities, it could not be centralised. Participants attended dedicated trial ultrasound clinics at the 13 RCs. Staffing these clinics for 11 years was very difficult given the shortage of trained staff and the need within the NHS to deliver the clinical service. We addressed this by organising clinics out of hours and on weekends so that NHS staff could perform scans. We also set up our own staff agency to enable ultrasonographers to work on a sessional basis in our scan clinics. We had to pay premium rates which were outside the NHS pay scale.

While pelvic scanning was widely available, most sonographers were used to scanning symptomatic patients with a high prevalence of clinical pelvic masses. We had to develop specific training for scanning of postmenopausal adnexa, an accreditation programme⁵⁶ with revalidation and quality assurance monitoring using ovarian visualisation rates.⁵⁶ These efforts required significant resources. In the future, the use of artificial intelligence algorithms for both ensuring quality and also classifying results is likely to make a significant impact on screening using imaging.

Retention and compliance with screening

From the start, we regularly emphasised to all trial staff the importance of retention if our successful recruitment efforts were to translate into an impactful trial. We were conscious that our resources to contact all participants individually were limited. We therefore made it a priority to ensure they could easily contact us. There was a dedicated trial phone line and a receptionist who manned it during working hours, at both the CC and each of the RCs. Participants were also able to contact the CC through a dedicated e-mail address that continues to be active even now after the end of the trial (ukctocs@ucl.ac.uk). During the trial, these means of communication were used mainly for rescheduling appointments and querying screening results. A key responsibility of trial teams was to ensure that participant messages on the answer phone or queries were answered within the next working day and that any discussions were noted on the electronic participant records. The latter ensured that conversations were seamless independent of who answered the phone, and participants did not have to repeat any relevant issues. Each opportunity was used to ensure that they understood that they were central to our efforts and their concerns/queries were being taken seriously. Additionally, the co-chief investigator reviewed any complaints raised by participants, and responded within 48 hours. No issue was too trivial, and all suggestions that might improve the participant journey were evaluated and implemented if feasible.

We also maintained engagement through two planned postal questionnaires, one sent 3–5 years post randomisation and the second in April 2014. Additionally, we were able to obtain separate funding to send a newsletter about 7 years post trial start and a 'thank you' card after the end of screening (details below) to all women. Regular trial update posters were displayed in the UKCTOCS clinics (phlebotomy or ultrasound scan clinics). This was, however, only available to women from the screening groups, who attended annually; we were less able to engage with those in the no screening (control) group. The challenge of carrying out a trial of the scale of UKCTOCS in 2001–5 was that many women did not have mobile phones or e-mail addresses. All the newsletters had to be printed/posted, at a significant cost. The mailing costs (over £50,000) were too high to sustain the annual newsletters which would have

been our preference. Over the last 20 years, the ever-increasing use of the internet and widespread uptake of e-mail, including by older populations, now makes this a feasible, cheap option. Trial teams can even create study apps to engage participants throughout the trial.⁵⁴ We included trial updates in ovarian cancer charity newsletters as we were aware that a proportion of our participants accessed these. Where possible, we reinforced the message that we wished to communicate more regularly but were restricted by lack of funds. A recent systematic map has found that of all the methods currently used to maintain engagement with trial participants (social media, internet sites, e-mail and TV/radio), the most effective are e-mail and text messaging.⁴⁴

All of our efforts resulted in high rates of overall retention and compliance²² with screening. Among women eligible to undergo screening, the overall compliance with attending for the entire annual screening episode, including repeat screens if required, was 81% in the MMS and 78% in the USS arms.^{22,38} This also reflects the commitment of the participants to contribute to research despite the length of the trial, the demands of annual attendance at screens or completion of questionnaires, and any possible psychological burden. A systematic review of 45 qualitative studies involving 1732 RCT participants reported that the effects included anxiety, the notion of 'being a guinea pig', and finding being randomised to the control arm difficult, which resulted in disappointment, anger and depression. Furthermore, they reported a range of psychological, physical, and financial burdens related to follow-up and trial closure. Poorly organised trials and follow-up that was very demanding were cited as some of the factors that affected participation. On the other hand, the trial participants reported taking part with satisfaction and the feeling of being 'useful', gaining 'a sense of control', and receiving special attention.⁵⁷

Follow-up

Access to routinely collected health data (RHCD) was an essential aspect of follow-up. As the primary end point was ovarian cancer mortality, women were linked using their NHS number to national cancer and death registration and hospital episode statistics (HES)/Patient Episode Database for Wales (PEDW) data. Written consent was obtained at recruitment. We had to revise the PIS to include specific mention of the ONS so that participants were aware that identifiable data would be shared with the organisation for the purposes of flagging. During the course of the trial, the ONS transferred this function to NHS Digital (formerly the Health and Social Care Information Centre, and prior to that the NHS Information Centre), which subsequently supplied HES data. Until 2014, the legal basis of data-sharing was consent. This included the 2010 Data-Sharing Agreement (DSA) with NHS Digital. However, in 2014, they declined to renew the DSA, stating that the consent was outdated. Reconsenting participants is usually only necessary where the original consent was flawed or there are significant changes in the research procedures, risks, potential benefits, or alternatives.⁵⁸ Given the large number of participants, it was not possible to recontact or reaffirm consent. We therefore had to apply to the Health Research Authority Confidentiality Advisory Group for approval under Regulation 5 of the Health Service (Control of Patient Information) Regulations 2002 to process patient-identifiable information without consent (Section 251). Approval was granted in April 2015. The NHS Digital processes seemed to be at odds with the participants' consent and wishes and the ethically approved scientific objectives of the project. This was supported by the fact that for the DSA renewal with NHS Wales Information Service, the chair of the Privacy Advisory Committee of Northern Ireland determined even in 2020 that the original express consent arrangements were a sufficient legal and ethical justification for disclosure of the information in question (patient-identifiable data) for the stated purpose of the trial. There have since been significant efforts by the Research Advisory Group within NHS Digital to advance the use and effectiveness of NHS Digital's data and services for the research community. Future trialists working in partnership with NHS Digital and NHS DigiTrials may be able to avoid the challenges we faced.

The recruitment and screening phases of UKTOCS pre-dated the introduction of the EU General Data Protection Regulation (GDPR), which came into effect in the UK on 25 May 2018. In order to comply with GDPR requirements, we published a privacy notice on our trial website.⁵⁹ In line with GDPR,

NHS Digital provided English and Welsh individuals the ability to opt out of allowing their personal information to be shared outside of NHS Digital for purposes beyond the individual's direct care (type 2 opt-out). Although we had explicit written consent which overrides type 2 opt-out, NHS Digital did not accept our participants' written consent as they felt it was not sufficiently current. Additionally, they stated that our PIS did not contain sufficient information detailing the use of personal identifiable data in matching to NHS Digital records. This meant that we had to obtain Section 251 approval for the legal basis for accessing NHS Digital data on UKCTOCS participants. NHS Digital did not share medical data of individuals who had opted out as per the terms of Section 251.

There is an increasing use of RCHD to inform or supplement outcome data.^{60,61} However, there is still no consensus on whether RCHD can be relied upon as the sole data source to determine outcome. One issue is that some participants will not appear on RCHD if they exit the registry due to immigration, imprisonment or military service. We therefore used additional data sources (three follow-up postal questionnaires, direct information from trial participants and their relatives and from RC staff as well as attendance at screening clinics) both to determine status (alive or dead) at censorship and to identify women who may have developed ovarian cancer. With regard to the latter, to ensure we cast as wide a net as feasible, we searched the RCHD data not only for *International Statistical Classification of Diseases and Related Health Problems*, Tenth Revision (ICD-10) codes for ovarian, tubal and primary peritoneal cancer but also for 16 other allied ICD-10 codes, including C80, disseminated malignancy of unknown origin. Postal follow-up at the end of the trial in 2020 helped us ensure we had as complete data as was possible. To be cost-effective, we limited mailing of this last questionnaire to 6586 participants on whom we had incomplete follow-up for a variety of reasons, such as difficulty ascertaining from HES data whether both ovaries had been removed, exiting from national registries etc. Even 20 years after trial start, we had a reasonable response rate of 38% (2493/6586) – in some cases, family members responded as the women had died.

As a result primarily of RCHD linkage, supplemented by the other sources listed above, we had complete follow-up for 98.9% of participants at our initial censorship (31 December 2014) and 95% at our final censorship (30 June 2020).⁶ We have previously reported on the detailed contribution of these data sources towards ascertaining our primary outcome.²² If we had only used RCHD data, we would have still been able to ascertain the majority of outcomes. Most important, sensitivity analyses determined that the results of the trial would not have changed if primary outcome events were restricted to those with either death or cancer registration.²² Given the latter finding and the costs of mailing follow-up questionnaires to over 200,000 participants, at scientific review of our proposal for extended follow-up, we were asked to omit the latter and limit follow-up to RCHD linkage. Nowadays there is less need to make such a choice based on costs due to the current ease of texting or e-mailing a survey link to participants. A more critical element in decision-making should be to weigh the pros and cons of the additional details that such questionnaires can provide for secondary and subgroup analyses. However, this must be balanced against the significant improvements in data quality of RCHD.

Independent Outcomes Review to ascertaining diagnosis and disease specific death

Given the lack of consensus on using RCHD data to ascertain primary outcomes, we used central adjudication by experts of collated medical notes of all women we identified as having possible ovarian cancer. It was extremely resource-intensive to retrieve copies of hospital and primary care notes and required a dedicated staff member at the CC and input initially from the RC trial teams and during extended follow-up from the local National Institute for Health and Care Research (NIHR) clinical research networks, individual site PIs and individual hospital records offices. The implementation of the 2020 updated Cancer Outcomes and Services Dataset (COSD, version 9.0) with more core mandatory elements is likely to improve the quality of centrally collected cancer data.⁶² This – together with the ability of trials with appropriate consent to access these data via NHS Digital,⁶³ and in time perhaps NHS DigiTrials⁶⁴ – will help decrease the time, effort and cost required to access such data.

Review and assignment of a primary cancer site, stage and cause of death required significant time commitment from extremely busy clinicians on the independent outcomes review committee.⁶⁵ If we had only used multiple RCHD sources, the sensitivity for ovarian and tubal cancer (World Health Organisation 2014) diagnosis would have been 91% (95% CI 89.4% to 92.5%) and that of death 94% (95% CI 91.9% to 95.5%). Furthermore, a sensitivity analysis for ovarian cancer death that only considered data obtained from electronic health records showed no evidence of a different result.⁶ Central adjudication improved the accuracy of diagnoses but in view of the effort involved, the gain was small. In future trials, there needs to be careful consideration of whether it is required as digital data collection and sharing processes improve.

We did not undertake pathological review of slides except in the occasional case where there was no consensus on diagnosis between outcome review committee members. The recent move to digital pathology services in the NHS has made pathological central review more feasible, and some trials are using it in real time both for adjudication and to improve patient outcomes.⁶⁶ These are still early days for this service and there are a number of challenges (e.g. pathologist training, validation studies for remote digital diagnoses) to be overcome. The ability to store digital pathology images of trial participants also means that secondary studies using machine learning and artificial intelligence techniques can be applied to discover and validate early detection, prognostic and predictive imaging biomarkers.

Maintenance and sustainability of bioresource

Written consent obtained for the trial included consent for banking of samples for future secondary studies. We used the available Medical Research Council (MRC) guidance on consent for biobanking of tissues. We included specific consent for any exceptions to future use of data or samples, especially sharing with commercial partners. A copy of the signed consent form was sent to the CC, where it was checked for completeness and entered on the TMS. This proved invaluable later when secondary projects were undertaken.

We denoted the bioresource created during the course of the UKCTOCS as the UKCTOCS Longitudinal Women's Cohort (UKLWC). It was separated from the main trial with its own dedicated access and governance structure to support wide and efficient sharing of samples and data with academia and industry. It consists of over half a million donated serum samples stored in ~500 µl aliquots (straws) in liquid nitrogen tanks. There are > 189,000 baseline samples from 189,452 women and a unique longitudinal set of 355,166 annual serial samples (median 9) from 50,262 women randomised to the MMS group. Given the age group of participants, RCHD linkage and current median follow-up of 16.3 years, many of the samples precede diagnosis of disease. The resource therefore provides an ideal setting for case-control studies for early detection biomarkers using the PRoBE (Prospective Specimen Collection Retrospective Blinded Evaluation) design.^{67,68} Longitudinal samples also provide a unique opportunity to improve biomarker performance for screening through the development of longitudinal algorithms.^{69,70} The UKLWC bioresource (samples and/or data) has to date supported ~70 collaborative projects (academic or commercial) and over 65 publications.⁵⁹

Generating and sustaining such a bioresource arising from a trial is a challenging endeavour. Most large biobanks in the UK, like UK Biobank³⁹ and the more recent Our Future Health research programme,⁷¹ are supported by significant public funding. As UKCTOCS was a trial, the focus of all funding agencies was on funding the main trial, and they were not supportive of creating a biobank. This view has since changed with increased understanding of the importance of translational research linked to trials. UKLWC was initially supported by the Barts Special Trustees and then the University College London Hospital (UCLH) Special Trustees, who provided funds to build and sustain the resource for a decade. When funding came to an end in 2011, we set up a University College London (UCL) spin-out company, Abcodia Ltd, with the aim to sustain the bioresource through commercial collaborations. Abcodia was granted an exclusive commercial licence to access UKLWC samples and data in all disease fields (2011–8) and then limited to early detection of cancer (2018–20). The funds from the licence supported the operational costs of the biobank (~£230,000 annually). This included space rental and maintenance costs of 25 liquid nitrogen tanks at a commercial cryofacility (2004–18 Fisher BioServices; 2018–2023 NIHR BioCentre) as well as the position of a research associate who coordinated (sample/data access and governance) the secondary research projects. While the arrangements worked for a few years, enough profits were not generated for Abcodia to continue. Meanwhile, multiple grant applications aimed solely at sustaining the bioresource for future research proved unsuccessful. Bridging support for 18 months was obtained from the UCL/UCLH Biomedical Research Centre. This allowed the UKCTOCS core academic team to develop a cost recovery model that could sustain the resource through research collaborations. It includes an initial small application fee for staff input into project design and a bespoke costing of the collaboration. The latter includes staff costs (contribution to design and interpretation of results, governance requirements, sample set identification and control matching, data set preparation), sample and data cost recovery (depending on rarity, number and volume of samples) and run-through of charges levied by the commercial biorepository facility for retrieval, aliquoting and shipping. These collaborations are funded through competitive grants and academic or commercial funds. While the efforts have allowed the academic team to generate enough funds in the last few years, to date it has been on an annual basis. We continue to work on other avenues to sustain this valuable resource. One option is establishing a pre-competitive genomics consortium to transform the UKCTOCS Biobank into an 'open research' platform for the study of common diseases and delivery of precision medicine.

Patient and public involvement

Involvement of the public and ovarian cancer patients in the design and conduct of UKCTOCS was mainly through the advocacy charities and their leadership. CEOs of these charities contributed to oversight of trial progress through membership of the trial steering committee. Their opinions were an integral component of the interpretation and dissemination of the results. Over the years, there has been an increasing focus on PPI, with more direct patient input into design, protocol development and trial outcomes.⁷² In the ReIMAGINE consortium, a PPI subcommittee is an integral part of the study workflow, contributing to study design and recruitment in addition to the analysis and dissemination. The subcommittee has a patient chair and a funded PPI coordinator. It has provided invaluable insights into study modifications due to COVID-19 restrictions.⁷³

We were keen to recognise the contribution of participants and express our gratitude to each individual volunteer in a unique and meaningful manner. To this end, we worked with Dr Lizzie Burn, an artist-scientist, to co-create an artwork that specifically reflected the ovarian cancer screening trials. After multiple discussions, she created a painting of the premenopausal ovary with its Graafian follicles (see [Appendix, Figure 1a](#)). Dr Burn's artwork conveyed the inherent beauty of these structures and evoked links to the oestrogen production that was critical to women throughout their lives. The original artwork was pixelated so that each dot represented eight participants (see [Appendix, Figure 1b](#)). The image was used on the cover of a 'thank you' card. The CC team created a 'Wordle' image for the back of the card, using words from the protocol, names of RCs and words that expressed our gratitude to the participants (see [Appendix, Figure 1c](#)). A 'thank you' message and details of trial progress were included inside the card (see [Appendix, Figure 1d](#)).

In April 2012, we posted 193,708 cards to all participants who we knew were alive. The envelope also included a letter addressed personally to each individual from the UKCTOCS PIs, Professors Jacobs and Menon, which explained what would happen in the passive follow-up phase of the trial, and a newsletter from the charity The Eve Appeal (TEA), which had also supported the research effort for UKCTOCS. TEA offered women the opportunity to sign up to its newsletters and so remain updated about UKCTOCS as well as other initiatives related to ovarian cancer. Within 3 weeks of posting, nearly 30,000 women responded in writing to TEA, increasing the charity newsletter's readership by sixfold. These responses included a number of positive comments about the trial (see [Appendix, Box 1](#)) and three letters of complaint. Engaging the trial participants in this way was a positive experience for all involved: the women, the charity and the trial team. We presented the public engagement project at our institute's annual meeting and used images of the artwork on our website and in scientific presentations. We are aware that our initiative has been used as an example of public engagement in PPI training workshops organised by UCL and in the undergraduate and postgraduate taught courses at our institute.

Now, with the trial complete, we have a UKCTOCS participant on the UKLWC data access committee so that participant views contribute to our efforts to maximise the scientific impact of the samples/data donated, through secondary research.

Dissemination of results

The recognition of UKCTOCS as the definitive trial globally for determining whether or not ovarian cancer screening in the general population could save lives meant that there was intense interest in its outcome. The team worked with the UCL press office and counterparts in the funder organisations to prepare the press release⁷⁴ to accompany the publication of the initial mortality analysis results in *The Lancet*. In addition, two public meetings to explain the findings and their implications were organised at the Royal College of Obstetrics and Gynaecology in London on 17 December 2015 to coincide with the publication. The meetings were streamed live. The first of these meetings was aimed at health professionals and the scientific research communities (<https://www.youtube.com/watch?v=gD8PGK3ieyw>), and a second meeting hosted by the ovarian cancer charities (TEA, Ovacom, Target Ovarian Cancer and Ovarian Cancer Action) (<https://www.youtube.com/watch?v=N8H6oN21rrw>) was for charities, advocacy and patient groups and the lay public. These groups included some participants. Approximately 400 individuals attended these meetings.

During the long-term follow-up phase of UKCTOCS, due to limited budgets, we were not able to reach out to the research and lay communities on a similar scale for the final reporting of the trial results in 2021. We created an animation explaining the trial results, which we shared on our website and using the Vimeo platform.⁷⁵ In the main, we relied on coverage of the trial results by the broadsheets and media services such as the BBC to disseminate the results to the public and participants.

Conclusion

Conducting UKCTOCS was possible because of a highly collaborative partnership approach involving staff in universities, NHS providers, funding agencies, charities and patient support groups, which started when the trial was conceived in the 1990s and was sustained for over 20 years. Keeping participants at the centre of all project management decisions, involvement of senior investigators in day-to-day running of the trial, proactive trial management, willingness to innovate and use technology were key to our success in delivering the trial. Significant engagement with participants ensured high rates of retention. Our solutions to the design, conduct and analysis issues we faced remain highly relevant, given the renewed focus on screening trials for early detection of cancer. Meanwhile there is a pressing need to increase the evidence base for trial methodology.

Acknowledgements

We thank the women who volunteered for their courage, generosity and time – without them there would not have been a trial. We thank all UKCTOCS investigators and staff for helping us conduct a trial where participants were central to all our efforts. The wider UKCTOCS team are listed here - <http://ukctocs.mrcctu.ucl.ac.uk/>. We are very grateful to the independent members of the UKCTOCS Trial Steering Committee: Henry Kitchener (Chair 2015–20), David Luesley (Chair 2001–14), Julietta Patnick, Jack Cuzick, Louise Bayne (2001–14) and Annwen Jones (2015–20) and the Data Monitoring and Ethics Committee [Peter Boyle (chair), Susanne Kjaer, Edward Trimble, and Peter Heintz]. We are indebted to Anna Widdup for the administrative support. We are very grateful to the funding agencies for their sustained support over many years.

Contributions of authors

Usha Menon (<https://orcid.org/0000-0003-3708-1732>) was the chief investigator from 2015 to 2020 and co-chief investigator from 2001 to 2014. She drafted the manuscript and prepared the figures and tables.

Aleksandra Gentry-Maharaj (<https://orcid.org/0000-0001-7270-9762>) contributed to the trial design and drafted the manuscript.

Matthew Burnell (<https://orcid.org/0000-0002-2632-1545>) contributed to the trial design, drafted the manuscript and prepared the figures and tables.

Sophia Apostolidou (<https://orcid.org/0000-0003-2659-0451>) drafted the manuscript.

Andy Ryan (<https://orcid.org/0000-0002-5359-9534>) contributed to the trial design and prepared the figures and tables.

Jatinderpal K Kalsi (<https://orcid.org/0000-0003-4615-5027>) drafted the manuscript.

Naveena Singh (<https://orcid.org/0000-0003-1782-1967>) contributed to the trial design.

Lesley Fallowfield (<https://orcid.org/0000-0003-0577-4518>) was a co-investigator and contributed to the trial concept and design.

Alistair J McGuire (<https://orcid.org/0000-0002-5367-9841>) was a co-investigator and contributed to the trial concept and design.

Stuart Campbell (<https://orcid.org/0000-0003-4943-155X>) was a co-investigator and contributed to the trial concept and design.

Steven J Skates (<https://orcid.org/0000-0001-9249-4316>) was a co-investigator and contributed to the trial concept and design.

Anne Dawnay (<https://orcid.org/0000-0001-6674-5986>) contributed to the trial design and drafted the manuscript.

Mahesh Parmar (<https://orcid.org/0000-0003-0166-1700>) was the trial statistician.

Ian J Jacobs (<https://orcid.org/0000-0002-5005-2672>) was the chief investigator from 2000 to 2014 and co-investigator from 2015 to 2020.

All contributed to review and revision of the manuscript. All authors approved the report before submission.

Ethics statement

The randomised controlled trial was approved in June 2000 by the UK North West Multicentre Research Ethics Committees (Ref: North West MREC 00/8/34), currently NRES Committee North West – Haydock, with site-specific approval from the local regional ethics committees and the Caldicott guardians (data controllers) of the 27 participating PCTs. All women provided written consent. Approval for follow-up of the entire cohort is until 31 December 2027.

The psychosocial study was approved by the North West research ethics committee (MREC 00/8/34), and separate written consent was obtained from all women. UKCTOCS was registered with ISRCTN number 22488978; ClinicalTrials.gov number NCT00058032.

Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review.

Funding

This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/46/01. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

The long-term follow-up UKCTOCS (2015–20) was supported by National Institute for Health and Care Research (NIHR HTA grant 16/46/01), Cancer Research UK, and The Eve Appeal. UKCTOCS (2001–14) was funded by the MRC (G9901012 and G0801228), Cancer Research UK (C1479/A2884), and the UK Department of Health, with additional support from The Eve Appeal. Researchers at UCL were supported by the NIHR UCL Hospitals Biomedical Research Centre and by the MRC Clinical Trials Unit at UCL core funding (MC_UU_00004/09, MC_UU_00004/08, MC_UU_00004/07). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health and Social Care.

This article

The contractual start date for this research was in January 2017. This article began editorial review in May 2022 and was accepted for publication in November 2022. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The *Health Technology Assessment* editors and publisher have tried to ensure the accuracy of the authors' article and would like to thank the reviewers for their constructive comments on the draft document.

However, they do not accept liability for damages or losses arising from material published in this article. This article was published based on current knowledge at the time and date of publication. NIHR is committed to being inclusive and will continually monitor best practice and guidance in relation to terminology and language to ensure that we remain relevant to our stakeholders.

Disclaimer

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

This article reports on one component of the research award Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials. For more information about this research please view the award page [<https://www.fundingawards.nihr.ac.uk/award/16/46/01>]

References

1. ISCRTN. *ISCRTN Registry of Clinical Studies* 2022. URL: <https://www.isrctn.com/search?q=randomised+controlled+&filters=GT+dateApplied%3A2010-01-01T00%3A00%3A00.000Z%2CLE+dateApplied%3A2021-12-31T00%3A00%3A00.000Z&searchType=advanced-search> (accessed 4 May 2022).
2. MRC. *MRC-NIHR Trials Methodology Research Partnership (TMRP) 2015*. URL: <https://www.methodologyhubs.mrc.ac.uk/about/tmrp/> (accessed 4 May 2022).
3. Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, *et al*. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. *BMJ Open* 2017;**7**(3):e015276.
4. Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrom M, Johansen M, *et al*. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. *BMJ Open* 2013;**3**(2):e002360.
5. Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, *et al*. Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. *Trials* 2011;**12**:61.
6. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, *et al*. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet* 2021;**397**(10290):2182–93.
7. CRUK. *Deprivation Gradient in Ovarian Cancer Mortality* 2014. URL: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/mortality#heading-Four> (accessed 4 May 2022).
8. Church TR, Ederer F, Mandel JS, Watt GD, Geisser MS. Estimating the duration of ongoing prevention trials. *Am J Epidemiol* 1993;**137**(7):797–810.
9. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, *et al*. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. *Am J Epidemiol* 2007;**165**(8):874–81.
10. CRUK. *Ovarian Cancer Statistics: Ovarian Cancer Mortality* 2018. URL: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-One> (accessed 25 August 2021).
11. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, *et al*. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. *Lancet* 1985;**1**(8433):829–32.
12. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, *et al*.; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet* 2010;**375**(9726):1624–33.
13. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, *et al*. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. *JAMA* 2014;**312**(6):606–15.

14. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, *et al.*; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;**365**(5):395–409.
15. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, *et al.*; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med* 2012;**366**(25):2345–57.
16. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, *et al.*; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;**360**(13):1320–8.
17. Etzioni RD, Thompson IM. What do the screening trials really tell us and where do we go from here? *Urol Clin North Am* 2014;**41**(2):223–8.
18. Hanley JA. Measuring mortality reductions in cancer screening trials. *Epidemiol Rev* 2011;**33**:36–45.
19. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, *et al.* The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. *Cancer* 1997;**80**(11):2091–9.
20. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. *Lancet Oncol* 2015;**16**(9):1123–32.
21. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, *et al.*; SCORE Working Group. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. *J Natl Cancer Inst* 2011;**103**(17):1310–22.
22. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, *et al.* Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet* 2016;**387**(10022):945–56.
23. Burnell M, Gentry-Maharaj A, Skates SJ, Ryan A, Karpinskyj C, Kalsi J, *et al.* UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. *Trials* 2021;**22**(1):173.
24. Royston P. Power and sample-size analysis for the Royston–Parmar combined test in clinical trials with a time-to-event outcome. *Stata J* 2018;**18**(4):995–6. <https://doi.org/10.1177/1536867X1801800414>
25. Royston P, Choodari-Oskoei B, Parmar MKB, Rogers JK. Combined test versus logrank/Cox test in 50 randomised trials. *Trials* 2019;**20**(1):172.
26. Karrison TG. Versatile tests for comparing survival curves based on weighted log-rank statistics. *Stata J* 2016;**16**(3):678–90.
27. DeSantis T, Chakhtoura N, Twiggs L, Ferris D, Lashgari M, Flowers L, *et al.* Spectroscopic imaging as a triage test for cervical disease: a prospective multicenter clinical trial. *J Low Genit Tract Dis* 2007;**11**(1):18–24.
28. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, *et al.*; STEPS group. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. *Health Technol Assess* 2007;**11**(48):iii, ix–105.
29. ISO. *Information Technology – Security Techniques – Information Security Management Systems – Requirements* 2013. URL: <https://www.iso.org/standard/54534.html> (accessed 4 May 2022).

30. NHS. *Data Security and Protection Toolkit 2022*. URL: <https://www.dsptoolkit.nhs.uk/> (accessed 4 May 2022).
31. Zhang J, Sun L, Liu Y, Wang H, Sun N, Zhang P. Mobile device-based electronic data capture system used in a clinical randomized controlled trial: advantages and challenges. *J Med Internet Res* 2017;**19**(3):e66.
32. Ruth CJ, Huey SL, Krisher JT, Fothergill A, Gannon BM, Jones CE, *et al*. An Electronic Data Capture Framework (ConnEDCt) for Global and Public Health Research: Design and Implementation. *J Med Internet Res* 2020;**22**(8):e18580.
33. Kasenda B, Liu J, Jiang Y, Gajewski B, Wu C, von Elm E, *et al*. Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)-rationale and design for an international collaborative study. *Trials* 2020;**21**(1):731.
34. Huang GD, Bull J, Johnston McKee K, Mahon E, Harper B, Roberts JN, *et al*.; CTTI Recruitment Project Team. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. *Contemp Clin Trials* 2018;**66**:74–9.
35. Desai M. Recruitment and retention of participants in clinical studies: critical issues and challenges. *Perspect Clin Res* 2020;**11**(2):51–3.
36. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, *et al*. Recruitment to multicentre trials – lessons from UKCTOCS: descriptive study. *BMJ* 2008;**337**:a2079.
37. NHS. *NHS Digitrials - Setting up the Trial 'NHS-GALLERI - a test designed to detect early signs of cancer' 2022*. URL: <https://digital.nhs.uk/services/nhs-digitrials#setting-up-the-trial> (accessed 4 May 2022).
38. Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT. Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment. *Health Technol Assess* 2003;**7**(26):iii, v-x, 1-117. doi:10.3310/hta7260. PMID: 14499049.
39. UKBiobank. *UK Biobank 2022*. URL: <https://www.ukbiobank.ac.uk/learn-more-about-uk-bio-bank/about-us> (accessed 4 May 2022).
40. Sullivan FM. Improving recruitment to clinical trials with a register of a million patients who agree to the use of their clinical records for research in the Scottish Health Research Register (SHARE). *Trials* 2011;**12**(Suppl 1):A115.
41. Staley H, Shiraz A, Shreeve N, Bryant A, Martin-Hirsch PP, Gajjar K. Interventions targeted at women to encourage the uptake of cervical screening. *Cochrane Database Syst Rev* 2021;**9**:CD002834.
42. Panopto. *Clinical Trial Video Communications: Building A Partnership with Patients Through Education 2018*. URL: <https://www.panopto.com/blog/video-for-clinical-trials-a-partnership-with-patients-through-education/> (accessed 4 May 2022).
43. PMLive. *Using Video to Enhance Clinical Trial Patient Recruitment and Retention 2020*. URL: https://www.pmlive.com/pmhub/clinical_research/couch_integrated_marketing/white_papers_and_resources/using_video_to_enhance_clinical_trial_patient_recruitment_and_retention (accessed 4 May 2022).
44. Frampton GK, Shepherd J, Pickett K, Griffiths G, Wyatt JC. Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. *Trials* 2020;**21**(1):478.

45. Avis NE, Smith KW, Link CL, Goldman MB. Increasing mammography screening among women over age 50 with a videotape intervention. *Prev Med* 2004;**39**(3):498–506.
46. Signorelli C, Wakefield CE, McLoone JK, Mateos MK, Aaronson NK, Lavoipierre A, *et al.*; ANZCHOG Survivorship Study Group. A cost-effective approach to increasing participation in patient-reported outcomes research in cancer: a randomized trial of video invitations. *Int J Cancer* 2021;**148**(4):971–80.
47. Treweek S, Bevan S, Bower P, Campbell M, Christie J, Clarke M, *et al.* Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)? *Trials* 2018;**19**(1):139.
48. York. *University of York – Trial Forge Studies Within A Trial (SWAT) Centre* 2022. URL: <https://www.york.ac.uk/healthsciences/research/trials/swats/> (accessed 4 May 2022).
49. Cockayne S, Adamson J, Bower P, Corbacho B, Fairhurst C, Farndon L, *et al.* The REFORM patient information sheet sub study – an embedded trial evaluating the enhancement of patient information sheets to improve recruitment. *Trials* 2015;**16**(Suppl. 2):P87. <https://doi.org/10.1186/1745-6215-16-S2-P87>
50. Hughes-Morley A, Hann M, Fraser C, Meade O, Lovell K, Young B, *et al.* The impact of advertising patient and public involvement on trial recruitment: embedded cluster randomised recruitment trial. *Trials* 2016;**17**(1):586.
51. Arundel C, Jefferson L, Bailey M, Cockayne S, Hicks K, Loughrey L, *et al.*; REFORM Study Team. A randomized, embedded trial of pre-notification of trial participation did not increase recruitment rates to a falls prevention trial. *J Eval Clin Pract* 2017;**23**(1):73–8.
52. Lewis H, Keding A, Bosanquet K, Gilbody S, Torgerson D. An randomized controlled trial of Post-It® Notes did not increase postal response rates in older depressed participants. *J Eval Clin Pract* 2017;**23**(1):102–7.
53. Mitchell N, Hewitt CE, Torgerson DJ, Group ST. A controlled trial of envelope colour for increasing response rates in older women. *Aging Clin Exp Res* 2011;**23**(3):236–40.
54. Antidote. *7 Clinical Trial Patient Recruitment and Retention Tips* 2022. URL: <https://www.antidote.me/blog/7-clinical-trial-recruitment-and-retention-tips> (accessed 4 May 2022).
55. Skates S. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. *J Am Stat Assoc* 2001;**96**(454):429–39.
56. Sharma A, Burnell M, Gentry-Maharaj A, Campbell S, Amso NN, Seif MW, *et al.* Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Ultrasound Obstet Gynecol* 2016;**47**(2):228–35.
57. Naidoo N, Nguyen VT, Ravaud P, Young B, Amiel P, Schante D, *et al.* The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. *BMC Med* 2020;**18**(1):6.
58. Resnik DB. Re-consenting human subjects: ethical, legal and practical issues. *J Med Ethics* 2009;**35**(11):656–7.
59. UKLWC. *Publications Utilising Samples and/or Data from the UKLWC Biobank* 2020. URL: <http://uklwc.mrcctu.ucl.ac.uk/publications/> (accessed 4 May 2022).
60. Lensen S, Macnair A, Love SB, Yorke-Edwards V, Noor NM, Martyn M, *et al.* Access to routinely collected health data for clinical trials – review of successful data requests to UK registries. *Trials* 2020;**21**(1):398.
61. McKay AJ, Jones AP, Gamble CL, Farmer AJ, Williamson PR. Use of routinely collected data in a UK cohort of publicly funded randomised clinical trials. *F1000Res* 2021;**9**:323.

62. NCRAS. *Cancer Outcomes and Services Dataset (COSD) 2010*. URL: http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd (accessed 30 September 2022).
63. NHS. *NHS Digital 2022*. URL: <https://digital.nhs.uk/> (accessed 30 September 2022).
64. NHS. *NHS Digitrials 2022*. URL: <https://digital.nhs.uk/services/nhs-digitrials#how-to-get-data-from-nhs-digitrials-for-your-research> (accessed 30 September 2022).
65. Kalsi JK, Ryan A, Gentry-Maharaj A, Margolin-Crump D, Singh N, Burnell M, *et al*. Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials—an ovarian cancer exemplar. *Trials* 2021;**22**(1):88.
66. Gaba F, Robbani S, Singh N, McCluggage WG, Wilkinson N, Ganesan R, *et al*.; PROTECTOR Team. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. *Int J Gynecol Cancer* 2021;**31**(2):286–91.
67. Feng Z, Kagan J, Pepe M, Thornquist M, Ann Rinaudo J, Dahlgren J, *et al*. The Early Detection Research Network’s specimen reference sets: paving the way for rapid evaluation of potential biomarkers. *Clin Chem* 2013;**59**(1):68–74.
68. Pepe MS, Li CI, Feng Z. Improving the quality of biomarker discovery research: the right samples and enough of them. *Cancer Epidemiol Biomarkers Prev* 2015;**24**(6):944–50.
69. Blyuss O, Burnell M, Ryan A, Gentry-Maharaj A, Marino IP, Kalsi J, *et al*. Comparison of longitudinal CA125 algorithms as a first-line screen for ovarian cancer in the general population. *Clin Cancer Res* 2018;**24**(19):4726–33.
70. Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, *et al*. Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women. *Cancers (Basel)* 2020;**12**(7):1931. <https://doi.org/10.3390/cancers12071931>
71. OurFutureHealth. *Our Future Health – Research Programme 2022*. URL: <https://ourfuturehealth.org.uk/research-programme/> (accessed 29 April 2022).
72. Crocker J, Hughes-Morley A, Petit-Zeman S, Rees S. Assessing the impact of patient and public involvement on recruitment and retention in clinical trials: a systematic review. *Trials* 2015;**16**(Suppl. 2):O91. <https://doi.org/10.1186/1745-6215-16-S2-O91>
73. Green S, Tuck S, Long J, Green T, Green A, Ellis P, *et al*. ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement. *Res Involv Engagem* 2021;**7**(1):81.
74. UKCTOCS. *Media Coverage 2021*. URL: <http://ukctocs.mrcctu.ucl.ac.uk/news/> (accessed 5 May 2022).
75. UKCTOCS. *Animated Abstract 2021*. URL: <https://vimeo.com/546075178> (accessed 4 May 2022).

Appendix

TABLE 1 UKCTOCS – ethnicity of women randomised by regional centre

Ethnicity	Regional centre												
	Gateshead (%)	Barts (%)	Liverpool (%)	Nottingham (%)	Manchester (%)	Derby (%)	Royal Free (%)	Portsmouth (%)	Bristol (%)	Belfast (%)	Cardiff (%)	North Wales (%)	Middlesbrough (%)
White	16,994 (98.1)	17,621 (88.1)	9979 (98.7)	16,434 (98)	16,184 (98.1)	14,710 (98.6)	14,048 (84.2)	18,978 (98.9)	16,385 (98.9)	13,539 (99.7)	16,535 (98.7)	14,007 (97.9)	9861 (99.4)
Black African	9 (0.1)	300 (1.5)	19 (0.2)	21 (0.1)	17 (0.1)	3 (0)	332 (2)	17 (0.1)	7 (0)	7 (0.1)	20 (0.1)	6 (0)	3 (0)
Black Caribbean	2 (0)	826 (4.1)	15 (0.1)	156 (0.9)	69 (0.4)	73 (0.5)	572 (3.4)	14 (0.1)	64 (0.4)	3 (0)	26 (0.2)	2 (0)	1 (0)
Black Other	2 (0)	49 (0.2)	19 (0.2)	11 (0.1)	11 (0.1)	5 (0)	58 (0.3)	6 (0)	8 (0)	(0)	10 (0.1)	6 (0)	(0)
Chinese	15 (0.1)	99 (0.5)	22 (0.2)	19 (0.1)	31 (0.2)	2 (0)	120 (0.7)	26 (0.1)	9 (0.1)	7 (0.1)	15 (0.1)	7 (0)	3 (0)
Indian	32 (0.2)	353 (1.8)	19 (0.2)	74 (0.4)	53 (0.3)	79 (0.5)	467 (2.8)	22 (0.1)	21 (0.1)	2 (0)	37 (0.2)	10 (0.1)	11 (0.1)
Bangladeshi	3 (0)	69 (0.3)	0 (0)	0 (0)	1 (0)	0 (0)	31 (0.2)	2 (0)	1 (0)	1 (0)	2 (0)	0 (0)	0 (0)
Pakistani	7 (0)	72 (0.4)	0 (0)	16 (0.1)	13 (0.1)	21 (0.1)	24 (0.1)	3 (0)	6 (0)	3 (0)	12 (0.1)	1 (0)	12 (0.1)
Other	40 (0.2)	418 (2.1)	20 (0.2)	26 (0.2)	82 (0.5)	19 (0.1)	865 (5.2)	67 (0.3)	48 (0.3)	7 (0.1)	65 (0.4)	20 (0.1)	18 (0.2)
Missing	222 (1.3)	189 (0.9)	17 (0.2)	13 (0.1)	42 (0.3)	11 (0.1)	176 (1.1)	45 (0.2)	25 (0.2)	6 (0)	36 (0.2)	249 (1.7)	13 (0.1)




FIGURE 1 UKCTOCS – ‘thank you’ card sent to all women at the end of active screening in 2012. (a) Original artwork – primary ovarian follicle; (b) pixelated image – each dot representing eight women who participated in UKCTOCS; (c) back of the card: ‘Wordle’ image; and (d) inside the card: (left) facts about UKCTOCS and (right) ‘thank you’ message to the women.

BOX 1 Examples of comments from UKCTOCS participants on receipt of the 'thank you' card

'I did not miss one appointment, it is very nice to know you are still thinking of us. Many thanks.'

'This saved my life!'

'Thank you, the card is amazing. I did it for all our daughters.'

'Proud to have taken part.'

'I have been very happy to be involved in this study and maybe one day it will be of help to other women such as my daughter or her friends.'

'It has been an absolute honour to take part in the trial and I so appreciate the card sent to acknowledge the end of the trial. It will become one of my "treasures"! Thank you for your work.'

'It's good to be appreciated, thank you for the card.'

'I thought that the card was really thoughtful and clever. I'd love to be kept in touch with your progress having been involved for so long and I wish you the successful outcome that all your efforts deserve so that this awful disease can be diagnosed as early as possible.'

'Thank you to all the team of UKCTOCS. I didn't have ovarian cancer but the test revealed I had womb cancer. I shall forever be in your debt.'

'I cannot express my gratitude for these trials and consider myself very fortunate. I am sure this will help many more women in the future.'

'I have to say I am so thankful to UKCTOCS and so, so glad I attended the clinic for a blood test for nine years, I dread to think what might have been the outcome if I had not.'